GENE ONLINE|News &
RemeGen
JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb
2026-01-15
AbbVie Bets $5.6 Billion on PD-1×VEGF Bispecifics, Licensing RemeGen’s RC148 to Expand Its Oncology Arsenal
2026-01-13
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05Partner
LATEST
Wendy Short Bartie Repositions Bristol Myers Squibb Corporate Affairs to Integrate Patient Advocacy and Healthcare Access
2026-09-14
Wendy Short Bartie Restructures Bristol Myers Squibb Corporate Affairs to Link Reputation with Business Performance
2026-09-14
Wendy Short Bartie Integrates Patient Advocacy and Public Trust into Bristol Myers Squibb Business Strategy
2026-09-14
Mycenax Teams Up with Global Partners to Expedite R&D and Market Launch of Next-Generation ADCs
2026-09-14
Chinese Bispecific Antibody Tops Keytruda in First Head-to-Head OS Win; SMA Muscle-Strengthening Therapy Approved, B7-H3 ADC Shows Promise
2026-09-14
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
